Substrate
finance

Aptose Biosciences Delays Closing of Hanmi Acquisition to June

Aptose Biosciences said regulatory approvals in South Korea are still pending for its planned acquisition by Hanmi Pharmaceutical. The companies now target closing in June and have received an additional loan advance to continue operations.

Benzinga
1 source·May 29, 11:30 AM(6 hrs ago)·1m read
|
Aptose Biosciences Delays Closing of Hanmi Acquisition to Juneetfdailynews.com
Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.

Aptose Biosciences Inc. announced on May 29, 2026 that the closing of its previously announced acquisition by Hanmi Pharmaceutical Co. Ltd. and its subsidiary has been delayed. Certain Korean regulatory approvals required for the transaction remain in progress. The parties stated they do not expect the review to prevent completion and now target closing for June.

Under the arrangement, Hanmi will acquire all common shares of Aptose not already owned by the Hanmi Purchasers. 88 on the Toronto Stock Exchange. The agreement was first disclosed on November 19, 2025.

0 million advance from Hanmi under an amended loan facility originally announced on September 22, 2025. 0 million advance expected in the coming days. These funds support continuation of the TUSCANY clinical trial evaluating tuspetinib in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia.

Key Facts

C$2.41 per share
cash consideration offered to Aptose shareholders
28% premium
above Aptose's 30-day VWAP of C$1.88
US$9.9 million
total drawn under the Hanmi loan facility to date
June 2026
new target month for closing the acquisition

Story Timeline

3 events
  1. September 22, 2025

    Aptose and Hanmi announced the US$11.9 million loan facility agreement.

    1 sourceBenzinga
  2. November 19, 2025

    Aptose disclosed the plan of arrangement with Hanmi Pharmaceutical.

    1 sourceBenzinga
  3. May 29, 2026

    Aptose reported that Korean regulatory approvals remain pending and moved closing target to June.

    1 sourceBenzinga

Potential Impact

  1. 01

    Shareholders will receive C$2.41 per share if the transaction closes as planned.

  2. 02

    Aptose will continue the TUSCANY clinical trial using funds from the Hanmi loan facility.

Transparency Panel

Sources cross-referenced1
Confidence score65%
Synthesized bySubstrate AI
Word count143 words
PublishedMay 29, 2026, 11:30 AM

Related Stories

SEC Chair Paul Atkins Says Congress Will Pass Crypto Legislationibtimes.com
finance52 min agoDeveloping

SEC Chair Paul Atkins Says Congress Will Pass Crypto Legislation

SEC Chair Paul Atkins stated he is confident Congress will pass crypto market structure legislation. He added that President Trump will sign the bill into law.

WA
BI
2 sources
Iran Says Strait of Hormuz Management Belongs to Iran and Omanasiaone.com
finance52 min agoDeveloping

Iran Says Strait of Hormuz Management Belongs to Iran and Oman

Iran's Foreign Ministry spokesperson stated that control of the Strait of Hormuz must be decided solely by Iran and Oman. The spokesperson also said no agreement has been reached with the United States and that current focus remains on ending the war.

DE
LI
ZE
IN
4 sources
Fed Official Highlights Regulatory Barriers to AI Productivity Gainscnbc.com
finance52 min agoDeveloping

Fed Official Highlights Regulatory Barriers to AI Productivity Gains

A Federal Reserve official stated that productivity growth remains key to economic expansion and that regulatory hurdles are the main obstacle to sustained gains from artificial intelligence.

FI
FI
2 sources